Esperion Therapeutics, Inc. (Nasdaq: ESPR) announced the publication of “Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE